What Ori Biotech does

Ori Biotech is a private UK-headquartered cell and gene therapy (CGT) manufacturing technology company that has developed the IRO® platform, a fully closed and automated system that integrates proprietary hardware, consumables, and software to transition cell therapy manufacturing seamlessly from R&D to GMP production. The core platform centers on a novel bellows bioreactor (50ml to 1L operating volume achieving up to 12B cells and ~170x fold expansion) and the patented OriConnect™ sterile fluid transfer system, combined with 21 CFR Part 11-compliant flexible software and a cloud-native architecture for remote monitoring and process optimization. The company targets four horizontal customer segments: cell and gene therapy developers, contract development and manufacturing organizations (CDMOs), academic medical centers, and large pharmaceutical companies. Ori generated its first clinical patient dose in May 2026 through a partnership with ImmuXell in China and holds one of the first FDA Advanced Manufacturing Technology (AMT) designations awarded since the program launched in 2024.

Ori Biotech sells the IRO platform and its consumables through direct enterprise sales and a Preferred Partner Network that includes Charles River Laboratories, CTMC, ElevateBio, Kincell Bio, MaxCyte, and Fresenius Kabi, among others. Revenue is generated via quote-based, multi-year platform contracts with no publicly disclosed pricing, though the company claims IRO reduces manufacturing costs by 30-50%, labor costs by 50-70%, and enables operation in GMP Grade C/D cleanrooms versus the Grade A/B required by legacy manual systems. The company is backed by institutional investors including Novalis LifeSciences (which led the $100M+ Series B in January 2022), Delin Ventures, and Northpond Ventures, and is governed by a board chaired by Dr. Annalisa Jenkins with Non-Executive Directors Tony Hunt and Henrik Andersen. Headquartered in London with North American operations in Philadelphia, Ori holds 207 patents globally and operates across North America, Europe, China, and Australia through 18-22 active partners as of mid-2026.

Name

Ori Biotech

Legal name

Oribiotech Limited

Website

https://oribiotech.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Ori Biotech develops the IRO® platform, a fully closed and automated manufacturing system that integrates hardware, consumables, and software to scale cell and gene therapies from R&D to GMP. It sells to therapy developers, CDMOs, academic medical centers, and large pharma.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy Manufacturing Platform

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Industrial Instruments For Measurement, Display, And Control (3823)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industries

Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE), Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces) (HLAAAJAG), Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)

Keywords

• Cell therapy manufacturing
• Gene therapy automation
• Bioreactor technology
• CGT manufacturing platform
• Bioprocessing consumables

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. IRO® Platform Sales: Ori Biotech generates revenue through the sale and deployment of its IRO® manufacturing platform, which includes proprietary hardware instruments, consumables, and associated software. The platform is sold to cell and gene therapy developers, CDMOs, academic medical centers, and large pharmaceutical companies for use in research, process development, and GMP manufacturing.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Ori Biotech develops and sells the IRO® Platform, a fully closed, automated manufacturing system for cell and gene therapies that integrates proprietary hardware (the IRO instrument), single-use consumables (including the patented OriConnect™ sterile fluid transfer system and the Novel Bellows Bioreactor with 50ml–1L operating range), and a flexible, 21 CFR Part 11 compliant software layer. The platform enables therapy developers, CDMOs, academic medical centers, and large pharma companies to run activation, transduction, and expansion in a single consumable, transitioning seamlessly from R&D to GMP manufacturing in lower-grade (C/D) cleanrooms while reducing manufacturing costs by 30–50% and labor costs by 50–70%.

Product overview

Ori Biotech offers the IRO® platform as its core unified product—a next-generation, fully closed, automated manufacturing system for cell and gene therapies. The platform integrates proprietary hardware (the IRO instrument with Novel Bellows Bioreactor), consumables (including the patented OriConnect™ System for sterile fluid transfer), and flexible software for process control and monitoring. The system enables seamless transition from R&D to GMP manufacturing on a single platform. Supporting the core platform, Ori provides the Ori Data Hub (with internal and partner data, case studies, and application notes), the Patient Access Tracker (tracking commercial cell therapy patient access), and the Ori Spotlight Podcast (industry insights). The platform was commercially launched in December 2024 and holds FDA Advanced Manufacturing Technology designation.

Differentiator

Problem solved

Functional benefit

Brands

• IRO: Next-generation automated cell and gene therapy manufacturing platform that automates better biology, accelerates development, and scales from R&D to GMP.

Products and services

• IRO® Platform A next-generation, fully closed, automated manufacturing platform for cell and gene therapies that integrates proprietary hardware, consumables, software, data, and analytics. The platform enables seamless transition from R&D to GMP manufacturing on a single system, increasing throughput, improving quality, and reducing costs for cell and gene therapy developers, CDMOs, AMCs, and pharmaceutical companies.
• OriConnect™ System A patented closed and automated sterile fluid transfer technology consumable for the IRO® platform. It enables aseptic processing and eliminates the need for manual tube welding during the cell therapy manufacturing process, minimizing dead volumes and reducing the risk of human error.
• Novel Bellows Bioreactor A wide operating volume bioreactor (50ml to 1L) consumable for the IRO® platform with an adjustable mixing mechanism supporting static, rocking, and compression modes. The flexible operating volume range allows activation, transduction, and expansion in one consumable, supporting up to 12B cells at ~170x fold expansion.

Quantifiable outcome

• Up to 3.5x higher transduced cell yield vs control systems
• +8 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core.

• AdAlta and Cell Therapies Pty LtdcoreStrategic or Co-development Partner · 21 April 2026MoU signed April 2026 to bring IRO platform to Australia and Asia Pacific. Goals include deploying IRO at CTPL for process development and clinical manufacturing; optimizing AdAlta's cellular immunotherapy pipeline for scalability and cost. Collaboration targets 10-50x higher throughput, shorter manufacturing times, 30-50% cost savings. Supports AdAlta's 'East to West' globalization strategy.
• ImmuXell BiotechcoreStrategic or Co-development Partner · 1 December 2025Strategic partnership formed December 2025. First patient dosed in May 2026 in investigator-initiated trial using ImmuXell's TCR-T cell therapy for solid tumors (KRAS G12V mutations including colorectal, pancreatic, and lung cancers). IRO platform deployed at ImmuXell's Shanghai facilities. First Ori Biotech collaboration in Asia Pacific. Partnership validates IRO platform as GMP-compatible manufacturing solution.
• Seattle Children's Research InstitutecoreStrategic or Co-development Partner · 11 November 2025Partnership to evaluate IRO platform in support of advancing CGT research and clinical development. SCRI contributed to development of Breyanzi. 13th partner actively using IRO platform. Evaluating how early adoption of automation can accelerate product development, drive enhanced consistency, and enable scalable manufacturing.
• MaxCytecoreTechnology or Integration · 11 June 2025Collaboration aimed at enhancing manufacturing efficiencies and expanding adoption of autologous cellular therapies. Integration of MaxCyte's ExPERT electroporation system with Ori's IRO platform for improved cell therapy manufacturing workflows.
• Preferred Partner Network (PPN) MemberscoreChannel Partner/ Reseller/ Distributor · 18 March 2025PPN includes Charles River Laboratories, CTMC (joint venture between Resilience and MD Anderson), ElevateBio, Kincell Bio, other leading CDMOs, and two Tier 1 pharma companies. Network accelerates commercialization of cell and gene therapies through collaborative deployment of IRO platform.
• Fresenius KabicoreTechnology or Integration · 10 December 2024Collaboration to advance modular, scalable manufacturing of cell and gene therapies. Integration of platforms to address manufacturing challenges and enable distributed manufacturing for therapy developers.

Scale indicators19 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cellares: Closest direct competitor - develops automated cell therapy manufacturing platforms (Cell Shuttle). Raised $612M and competes head-to-head with Ori's IRO for the same cell therapy developer, CDMO, and pharma customers.
• Miltenyi Biotec: Offers the Prodigy and MACS platforms for automated cell processing and manufacturing, directly competing with IRO in the cell therapy manufacturing automation space, particularly for CAR-T and similar autologous therapies.

Broad incumbents

• Cytiva (Danaher): Global bioprocessing incumbent with broad cell therapy workflow solutions (including Sefia, Xuri, and cell expansion systems). Competes with Ori at the broader workflow level rather than as a purpose-built CGT platform; Ori's CTO Stuart Milne previously led R&D teams at Cytiva's predecessor (Asymptote/GE Healthcare).
• Thermo Fisher Scientific: Major life sciences tools and bioprocessing supplier (Gibco CTS, CTS Rotea counterflow centrifugation system) overlapping with IRO's customer base. Ori's board director Paul Meister is former Thermo Fisher Chairman.
• Lonza Group: World's largest CDMO with extensive cell and gene therapy manufacturing services and bioprocessing tools. Competes as both a customer (via Ori partners like Minaris) and indirectly as an integrated platform provider.
• Sartorius AG: Major bioprocessing equipment manufacturer offering bioreactors and cell processing platforms. Ori's Hardware Associate Director Mark Varley previously held roles at Sartorius Stedim Biotech.

Emerging players

• MaxCyte: Provider of electroporation technology (ExPERT platform) for cell engineering with strategic integration partnership with Ori. Former CFO Amanda Murphy is now an Ori advisor. Adjacent rather than head-to-head competitor.
• BioLife Solutions: Supplies biopreservation and cold chain solutions for cell therapies; complementary rather than competing with IRO platform, but serves the same CGT manufacturing customer base. Ori strategic advisor Mike Rice is former BioLife CEO.

Others

• Fresenius Kabi: Global healthcare company with cell therapy manufacturing solutions (Cellvite/CABALETTE) partnered with Ori for integration. Adjacent rather than direct competitor.
• Charles River Laboratories: Major CDMO and CGT manufacturer that is also an Ori Preferred Partner Network member and customer. More a partner/customer than direct competitor, but could develop competing internal platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/oribiotech

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles39 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ori Biotech